Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial

BACKGROUND: There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's dise...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lancet Gastroenterol Hepatol 2024-12, p.S2468-1253(24)00272
Hauptverfasser:	Vermeire, Séverine, Schreiber, Stefan, Rubin, David T, D'Haens, Geert, Reinisch, Walter, Watanabe, Mamoru, Mehta, Rajiv, Roblin, Xavier, Beales, Ian, Gietka, Piotr, Hibi, Toshifumi, Hospodarskyy, Ihor, Ritter, Timothy, Genovese, Mark C, Kwon, Paul, Santermans, Eva, Le Brun, Franck-Olivier, Barron, Rahul, Masior, Tomasz, Danese, Silvio
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!